MCID: BLD008
MIFTS: 30

Bladder Carcinoma in Situ

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Carcinoma in Situ

MalaCards integrated aliases for Bladder Carcinoma in Situ:

Name: Bladder Carcinoma in Situ 12 15
Flat Cis of the Urinary Bladder 12
Carcinoma in Situ of Bladder 12
Bladder Ca in Situ 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9053
ICD9CM 34 233.7
NCIt 49 C3644
SNOMED-CT 67 92546004
ICD10 32 D09.0
UMLS 71 C0154091

Summaries for Bladder Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the bladder.

MalaCards based summary : Bladder Carcinoma in Situ, also known as flat cis of the urinary bladder, is related to in situ carcinoma and gall bladder carcinoma in situ. An important gene associated with Bladder Carcinoma in Situ is MIR139 (MicroRNA 139). The drugs Sirolimus and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include bladder, prostate and bone.

Related Diseases for Bladder Carcinoma in Situ

Graphical network of the top 20 diseases related to Bladder Carcinoma in Situ:



Diseases related to Bladder Carcinoma in Situ

Symptoms & Phenotypes for Bladder Carcinoma in Situ

Drugs & Therapeutics for Bladder Carcinoma in Situ

Drugs for Bladder Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
2
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
3
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
4
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
5
Durvalumab Approved, Investigational Phase 2 1428935-60-7
6
BCG vaccine Investigational Phase 2
7 Antibiotics, Antitubercular Phase 1, Phase 2
8 Anti-Infective Agents Phase 1, Phase 2
9 Antiviral Agents Phase 1, Phase 2
10 Anti-Bacterial Agents Phase 1, Phase 2
11 Antifungal Agents Phase 1, Phase 2
12 Immunosuppressive Agents Phase 1, Phase 2
13 Antimetabolites Phase 1, Phase 2
14 Vaccines Phase 2
15 Antibodies, Monoclonal Phase 2
16 Antineoplastic Agents, Immunological Phase 2
17 Adjuvants, Immunologic Phase 2
18 Immunologic Factors Phase 2
19 Antibodies Phase 2
20 Immunoglobulins Phase 2
21
Altretamine Approved Phase 1 645-05-6 2123
22
Valrubicin Approved 56124-62-0 41744

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase I/II Study of RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder Completed NCT01259063 Phase 1, Phase 2 Everolimus and Intravesical Gemcitabine
2 A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder Recruiting NCT02901548 Phase 2 Durvalumab
3 A First-in-Human Phase I Study of Intravesical sEphB4-HSA in Patients With "BCG-Unresponsive" Bladder Carcinoma In Situ (CIS), Completely Resected High Grade Ta/T1, to Establish the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D) Not yet recruiting NCT03552796 Phase 1
4 A Retrospective Analysis to Evaluate the Effectiveness, Safety and Tolerability of Intravesical Valrubicin for the Treatment of Bladder Carcinoma in Situ in Clinical Practice Completed NCT01304173

Search NIH Clinical Center for Bladder Carcinoma in Situ

Genetic Tests for Bladder Carcinoma in Situ

Anatomical Context for Bladder Carcinoma in Situ

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Carcinoma in Situ:

19
Bladder

MalaCards organs/tissues related to Bladder Carcinoma in Situ:

40
Prostate, Bone, Heart, Cervix, B Cells

Publications for Bladder Carcinoma in Situ

Articles related to Bladder Carcinoma in Situ:

(show top 50) (show all 99)
# Title Authors PMID Year
1
A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'. 61
31487881 2019
2
Tuberculous Orchitis Following Intravesical Bacille Calmette-Guérin (BCG) Therapy. 61
30062077 2018
3
Educational Case: Bladder Carcinoma In Situ. 61
30140732 2018
4
Probe-Based Confocal Laser Endomicroscopy Using Acrinol as a Novel Dye Can Be Used to Observe Cancer Nuclei of Bladder Carcinoma In Situ. 61
29503871 2018
5
Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation. 61
28796929 2017
6
5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer. 61
28191719 2017
7
Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. 61
27664578 2017
8
Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases. 61
28994883 2016
9
Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin. 61
26777259 2016
10
Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy? 61
27072170 2016
11
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. 61
25466937 2015
12
Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ? 61
25660358 2015
13
Complication of treatment of carcinoma in situ of the bladder with photodynamic targeted cystodiathermy. 61
25245722 2014
14
Cancer identified incidentally in the prostate following radical cystoprostatectomy: an Australian study. 61
23216652 2014
15
Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided? 61
23551700 2014
16
Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra. 61
24144432 2014
17
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. 61
22575238 2013
18
Bladder carcinoma in situ (CIS) in Australia: a rising incidence for an under-reported malignancy. 61
23573811 2013
19
p16(INK4a) /Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology. 61
23003335 2013
20
Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation. 61
23576657 2013
21
A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. 61
23410519 2013
22
Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. 61
23383616 2013
23
Penile tuberculosis following intravesical Bacille Calmette-Guérin immunotherapy. 61
23671370 2013
24
Carcinoma in situ of urinary bladder: incidence, treatment and clinical outcomes during ten-year follow-up. 61
23115943 2012
25
[Tubercular prostatic abscess following intravesical Bacillus Calmette-Guerin therapy]. 61
22495047 2012
26
Early detection of carcinoma in situ of the bladder: a comparative study of white light cystoscopy, narrow band imaging, 5-ALA fluorescence cystoscopy and 3-dimensional optical coherence tomography. 61
22245332 2012
27
Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ. 61
21566413 2011
28
Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. 61
21167566 2011
29
The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor. 61
21169349 2011
30
Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guérin therapy. 61
22140647 2011
31
Cyclin D3 gene amplification in bladder carcinoma in situ. 61
20821231 2010
32
Enhancing detection of bladder carcinoma in situ by 3-dimensional optical coherence tomography. 61
20723922 2010
33
Clinical outcome of primary versus secondary bladder carcinoma in situ. 61
20620399 2010
34
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. 61
20546806 2010
35
Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder. 61
19957324 2010
36
A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer. 61
21358881 2010
37
The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy. 61
18440839 2009
38
Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. 61
19237175 2009
39
Relaxation training and guided imagery for an elderly man with bladder cancer: a case report. 61
20671329 2009
40
Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. 61
18423745 2008
41
[BCG infection of the glans penis after intravesical BCG therapy]. 61
18598797 2008
42
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. 61
17689003 2008
43
Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer. 61
17487406 2007
44
Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. 61
19034342 2007
45
Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer. 61
16517187 2006
46
Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. 61
16890661 2006
47
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. 61
16301114 2005
48
Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy. 61
16323989 2005
49
[Early diagnosis of bladder carcinoma]. 61
17877124 2005
50
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. 61
15610101 2004

Variations for Bladder Carcinoma in Situ

Expression for Bladder Carcinoma in Situ

Search GEO for disease gene expression data for Bladder Carcinoma in Situ.

Pathways for Bladder Carcinoma in Situ

GO Terms for Bladder Carcinoma in Situ

Biological processes related to Bladder Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of ERK1 and ERK2 cascade GO:0070373 8.96 PSCA MIR133A1
2 negative regulation of cardiac muscle cell apoptotic process GO:0010667 8.62 MIR199B MIR133A1

Sources for Bladder Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....